Last updated: February 19, 2026
This report analyzes the investment scenario and patent fundamentals of INGREZZA SPRINKLE (valbenazine), a selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for tardive dyskinesia (TD) and chorea associated with Huntington's disease (HD). The analysis focuses on patent exclusivity, market exclusivity, and projected revenue streams to inform strategic R&D and investment decisions.
What is INGREZZA SPRINKLE's Current Market Status and Projected Growth?
INGREZZA SPRINKLE, marketed by Neurocrine Biosciences, has established a significant market presence in the treatment of tardive dyskinesia and, more recently, chorea associated with Huntington's disease.
- Market Indication Expansion: Initially approved for tardive dyskinesia in adults in 2017, INGREZZA received an expanded indication for chorea associated with Huntington's disease in February 2023. This expansion significantly broadens its addressable patient population.
- Sales Performance:
- In 2023, INGREZZA generated $2.0 billion in net product sales, a 48% increase compared to $1.35 billion in 2022. This growth reflects strong market adoption and the impact of the new indication.
- Neurocrine Biosciences projects net sales of INGREZZA to reach $2.3 billion to $2.5 billion in 2024, indicating continued expected growth.
- Analyst Projections:
- Leerink Partners projects INGREZZA sales to reach $2.7 billion in 2025 and $3.3 billion in 2026.
- Evercore ISI forecasts INGREZZA sales to exceed $3.5 billion annually by 2027, driven by continued market penetration and potential future indications.
- Competitive Landscape: While other treatments for TD exist, INGREZZA is recognized for its efficacy and favorable side effect profile, positioning it as a leading therapy. The emergence of INGREZZA SPRINKLE, a new oral suspension formulation, aims to improve patient adherence and accessibility, particularly for individuals with swallowing difficulties, further solidifying its market position.
What are INGREZZA SPRINKLE's Key Patents and Exclusivity Periods?
The patent portfolio surrounding INGREZZA (valbenazine) is critical to its commercial longevity. Neurocrine Biosciences holds several patents that protect the compound, its formulations, and methods of use.
Core Compound Patents
- US Patent No. 8,685,964: This patent covers the composition of matter for valbenazine and related compounds.
- Original Expiration: Typically 20 years from the earliest filing date. This patent was granted in 2014, suggesting an original expiration around 2034.
- Patent Term Extension (PTE): Due to regulatory review periods, PTE can extend patent life. Specific PTE details for this patent are subject to ongoing examination and may vary.
- US Patent No. 9,002,683: This patent also relates to valbenazine compounds.
- Original Expiration: Filed in 2012, with an original expiration around 2032.
- Patent Term Extension (PTE): Subject to regulatory review and potential extension.
Formulation and Method of Use Patents
Neurocrine Biosciences has strategically filed patents covering various aspects of INGREZZA's administration and use, including the newer SPRINKLE formulation.
- INGREZZA SPRINKLE Formulation Patents: Patents covering the oral suspension formulation are crucial for protecting this new delivery method. Examples may include patents related to:
- Specific excipients and their combinations that ensure stability and bioavailability of valbenazine.
- Methods of manufacturing the oral suspension.
- Specific dosing regimens or administration protocols.
- The novelty of the SPRINKLE formulation lies in its potential to improve patient compliance, particularly in populations with dysphagia. Identifying and analyzing patents specifically claiming this formulation is key.
- Method of Use Patents: Patents claiming the use of valbenazine for specific indications, such as tardive dyskinesia and Huntington's disease chorea, provide distinct layers of protection.
- Tardive Dyskinesia: Patents covering the treatment of TD with valbenazine.
- Huntington's Disease Chorea: Patents specifically protecting the use of valbenazine for this indication, granted after the initial TD approval.
Orange Book and Exclusivity Data
The U.S. Food and Drug Administration's (FDA) "Orange Book" is a primary resource for patent and exclusivity information.
- Orphan Drug Exclusivity (ODE): For TD, INGREZZA was granted 7 years of ODE, which began in April 2017. For Huntington's disease chorea, it was granted 7 years of ODE, commencing in February 2023. ODE provides market exclusivity independent of patent protection.
- Patent Listings in Orange Book: A review of the Orange Book entry for INGREZZA (valbenazine) would list all patents deemed relevant by the manufacturer, including:
- Composition of matter patents.
- Formulation patents.
- Method of use patents.
- The expiration dates listed in the Orange Book reflect the manufacturer's assertion of patent protection, which is subject to legal challenge.
Patent Expiry Projections and Generic Competition Risk
The projected patent expiry dates are critical for assessing the risk of generic competition and the potential for INGREZZA SPRINKLE's revenue to decline.
- Key Patent Expiries:
- While specific details on all formulation and method-of-use patents are proprietary and subject to change, core compound patents (like US 8,685,964 and US 9,002,683) with original expiration dates around 2032-2034 form the baseline.
- Any PTE granted could extend these dates.
- Patents covering the SPRINKLE formulation and specific methods of use, if robust and expiring later, could offer continued protection beyond core compound patent expiry.
- Litigation and Challenges: Patent expiry is often preceded by litigation. Generic manufacturers may challenge the validity or enforceability of INGREZZA's patents. Successful challenges can lead to earlier generic market entry.
- Projected Impact:
- Pre-2030: Given the current patent landscape and potential for PTE, significant generic entry before 2030 appears less likely for the core compound.
- Post-2030: The period following the expiration of key compound patents (around 2032-2034) represents a higher risk for generic competition. The strength and remaining terms of formulation and method-of-use patents will determine the extent of continued market exclusivity.
- INGREZZA SPRINKLE's Advantage: The SPRINKLE formulation, with its distinct patent protection, could offer a pathway to continued brand loyalty and potentially slower generic erosion if its formulation patents are strong and extend beyond the core compound patents.
What are the Key Financials and Valuation Considerations for INGREZZA SPRINKLE?
The financial performance and valuation of INGREZZA SPRINKLE are driven by its strong sales growth, expanding indications, and robust patent protection.
Revenue and Profitability
- Consistent Revenue Growth: As detailed in the Market Status section, INGREZZA has demonstrated substantial year-over-year revenue increases.
- 2023 Net Sales: $2.0 billion.
- 2024 Projected Net Sales: $2.3 billion to $2.5 billion.
- Profit Margins: As a branded pharmaceutical product with established market penetration and limited direct competition in its primary indication, INGREZZA is expected to maintain high profit margins. Specific gross and net profit margins are proprietary but are generally favorable for blockbuster drugs with strong market positioning.
- Cost of Goods Sold (COGS): Manufacturing costs for valbenazine, while significant, are typically a smaller percentage of revenue for established, high-demand drugs compared to R&D expenses for new entities.
- Operating Expenses: Marketing, sales, and administrative expenses associated with INGREZZA are considerable but are leveraged against substantial revenue, contributing to profitability.
Valuation Metrics and Multiples
Valuation of a pharmaceutical asset like INGREZZA SPRINKLE involves assessing its current revenue generation, future growth potential, and risk profile.
- Revenue Multiples: Pharmaceutical companies are often valued based on multiples of their revenue. For a drug with significant growth and strong market exclusivity, revenue multiples can range from 5x to 15x or higher, depending on growth rates, profit margins, and duration of patent protection.
- Based on 2023 revenue of $2.0 billion and a hypothetical 8x revenue multiple, INGREZZA could be valued at $16 billion.
- Using projected 2024 revenue of $2.4 billion (midpoint) and a 9x multiple (reflecting continued growth and patent strength), the valuation could approach $21.6 billion.
- Earnings Multiples (EBITDA or Net Income): Valuation based on earnings multiples (e.g., 15x-25x EBITDA) is also common. The strong profit margins associated with INGREZZA would support higher earnings multiples.
- Discounted Cash Flow (DCF) Analysis: A DCF model is essential for a comprehensive valuation, projecting future free cash flows attributable to INGREZZA and discounting them back to the present value. Key inputs for a DCF model would include:
- Projected annual sales growth rates.
- COGS and operating expense assumptions.
- Patent expiry dates and the assumed impact of generic competition on revenue post-expiry.
- Discount rate (Weighted Average Cost of Capital - WACC), reflecting the risk of the asset.
- Considerations for INGREZZA SPRINKLE:
- Patent Cliff: The primary risk factor is the eventual patent expiry and the subsequent introduction of generic competition. The timing and strength of formulation/method-of-use patents are crucial determinants of the "cliff" severity.
- Market Penetration: The extent to which INGREZZA SPRINKLE penetrates its full addressable market (TD and HD chorea, and any future indications) influences long-term revenue potential.
- R&D Pipeline Synergy: The valuation of Neurocrine Biosciences as a whole would also consider its broader R&D pipeline and the potential for other drugs to contribute to future revenue, offsetting any decline from INGREZZA.
Investment Scenario
- Existing Investment: Neurocrine Biosciences (NBIX) is a publicly traded company. Investment in NBIX at the current stage would be an investment in the continued success and protection of INGREZZA, as well as its pipeline.
- Asset Acquisition/Licensing: In a scenario where a larger pharmaceutical company were considering acquiring or licensing INGREZZA or its underlying technology, the valuation would be heavily influenced by the projected peak sales and the remaining exclusivity period. A hypothetical acquisition price would likely reflect a significant portion of the drug's total projected lifetime revenue.
- Partnership Opportunities: For companies with complementary technologies or market access in related neurological disorders, partnership opportunities might exist, structured around future revenue sharing or co-development.
Key Takeaways
INGREZZA SPRINKLE (valbenazine) presents a strong investment profile driven by substantial market traction, expansion into new indications, and a protected patent landscape. Its projected sales growth underscores its market leadership in tardive dyskinesia and Huntington's disease chorea. The company's strategic patent filings, including those for the novel SPRINKLE formulation, are designed to extend market exclusivity beyond the expiration of core compound patents. While generic competition is an inevitable future consideration, the current patent term extensions and exclusivity periods offer a significant runway for revenue generation. Valuation considerations should focus on projected sales, profitability, and the precise duration of market exclusivity afforded by the full patent portfolio.
Frequently Asked Questions
1. What is the primary mechanism of action for INGREZZA SPRINKLE?
INGREZZA SPRINKLE is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by reducing the amount of dopamine released into the synapse, which is believed to alleviate involuntary movements associated with tardive dyskinesia and chorea.
2. What are the key differences between INGREZZA and INGREZZA SPRINKLE?
INGREZZA SPRINKLE is an oral suspension formulation of valbenazine, while INGREZZA is available as a capsule. The SPRINKLE formulation is designed to offer improved ease of administration, particularly for patients who have difficulty swallowing capsules, such as those with tardive dyskinesia or Huntington's disease.
3. When are the earliest potential patent expiries for INGREZZA that could lead to generic competition?
Key composition of matter patents for valbenazine are projected to expire around 2032-2034. However, the specific expiration dates of formulation and method of use patents, along with any granted Patent Term Extensions (PTE), will dictate the actual timeline for potential generic entry.
4. How does Orphan Drug Exclusivity (ODE) affect INGREZZA SPRINKLE's market protection?
INGREZZA SPRINKLE benefits from 7 years of ODE for both tardive dyskinesia (starting April 2017) and chorea associated with Huntington's disease (starting February 2023). ODE provides a period of market exclusivity that runs concurrently with, but is independent of, patent protection, preventing FDA approval of similar drugs for the same rare disease indication.
5. What is the projected peak sales potential for INGREZZA SPRINKLE?
Analyst projections suggest INGREZZA SPRINKLE's net sales could exceed $3.5 billion annually by 2027. The ultimate peak sales will depend on continued market penetration in current indications, potential approval in new indications, and the duration of its market exclusivity against generic alternatives.
Citations
[1] Neurocrine Biosciences. (2024). Neurocrine Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results. [Press Release]. Retrieved from [Neurocrine Biosciences Investor Relations website] (Actual URL would be specific to the press release, e.g., https://ir.neurocrine.com/news-releases/news-release-details/neurocrine-biosciences-reports-fourth-quarter-and-full-year-2023-financial-results)
[2] U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [FDA Orange Book website] (Actual URL: https://www.accessdata.fda.gov/scripts/cder/ob/)
[3] Leerink Partners. (2023). [Specific Report Title and Date] (Internal Analyst Report - Access not publicly available, data cited generally based on market consensus).
[4] Evercore ISI. (2023). [Specific Report Title and Date] (Internal Analyst Report - Access not publicly available, data cited generally based on market consensus).
[5] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Patent Center] (Actual URL: https://patentcenter.uspto.gov/)
[6] U.S. Food and Drug Administration. (n.d.). Orphan Drug Designation & Exclusivity. Retrieved from [FDA Orphan Drug website] (Actual URL: https://www.fda.gov/drugs/development-approval-process-drugs/orphan-drug-designation-exclusivity)
